Altshuler Shaham Ltd Takes $1.41 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Altshuler Shaham Ltd bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent filing with the SEC. The fund bought 27,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,414,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rise Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter worth about $25,000. Whittier Trust Co. purchased a new position in Halozyme Therapeutics in the first quarter valued at approximately $27,000. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics during the second quarter valued at $33,000. Finally, Principal Securities Inc. purchased a new stake in Halozyme Therapeutics in the fourth quarter worth $34,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 0.4 %

Shares of NASDAQ HALO opened at $59.24 on Monday. The company has a market cap of $7.54 billion, a price-to-earnings ratio of 24.48, a PEG ratio of 0.57 and a beta of 1.28. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The firm’s fifty day moving average is $58.40 and its 200 day moving average is $49.25. Halozyme Therapeutics, Inc. has a 52 week low of $32.83 and a 52 week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent research reports. Benchmark reaffirmed a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Insider Buying and Selling

In other news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $40,063,244.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock valued at $4,888,184 over the last quarter. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.